PsyCan Welcomes Expansion of Insurance Coverage for Psychedelic-Assisted Therapy in Alberta
April 02, 2024 09:30 ET
|
Psychedelics Canada
Psycan announces that Blue Cross Alberta has issued a notice to prescribers that it will reimburse patients for Psychedelic-Assisted Therapy
Optimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin Extract
April 02, 2024 07:30 ET
|
Optimi Health Corp.
Optimi receives Certificate Of Analysis for GMP Natural Psilocybin Extract. Company has also completed the in-house encapsulation of 5mg & 10mg psilocybin.
Optimi Health Confirms Presenting Sponsorship at the 4th Annual Psychedelic Therapeutics and Drug Development Conference
March 28, 2024 07:30 ET
|
Optimi Health Corp.
Optimi Health secures Presenting Sponsorship at the highly anticipated 4th Annual Psychedelic Therapeutics and Drug Development Conference in Boston, MA.
atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
March 28, 2024 07:00 ET
|
atai Life Sciences
Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato®Initial BPL-003...
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
March 27, 2024 08:00 ET
|
PharmAla Biotech
PharmAla recieves Allowance from USPTO for its lead drug candidate, a next-generation MDMA composition paving the way for clinical trials
atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression
March 27, 2024 07:00 ET
|
atai Life Sciences
- A single dose of BPL-003 demonstrated a rapid and durable antidepressant effect in TRD patients, with 45% of patients in clinical remission at week 12 - 55% of patients achieved a clinical response...
PharmAla Biotech Signs Sale Agreement with Numinus
March 26, 2024 08:55 ET
|
PharmAla Biotech
PharmAla announces binding sales order from Numinus Wellness, as well as a recent presentation of data to the Behaviour, Biology, and Chemistry Conference
Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University
March 26, 2024 07:30 ET
|
Optimi Health Corp.
Supply agreement marks Optimi’s first international shipment of research-grade active pharmaceutical ingredient (API) MDMA to Israel
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
March 20, 2024 10:20 ET
|
PharmAla Biotech
PharmAla Recieves Notice of Allowance of Patent on Novel MDMA-like Molecule with improved safety, therapeutic range
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
March 18, 2024 08:55 ET
|
PharmAla Biotech
PharmAla's 50:50 Joint Venture with Vitura Health Limited, Cortexa, announces it is first entity to supply Psilocybin into Authorized Prescriber Scheme